Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9750800 | 0.80 | RIPK1 (0.31) | — | |
| SCHEMBL20344584 | 0.78 | RIPK1 (0.30) | — | |
| SCHEMBL1877496 | 0.74 | — | — | |
| SCHEMBL12061285 | 0.73 | LMNA (0.39) | THRBLMNA | |
| SCHEMBL26274668 | 0.73 | — | — | |
| SCHEMBL127172 | 0.73 | — | — | |
| Hydrogen Sulfide SCHEMBL27817780 | 0.72 | THRB (0.38) | THRBLMNA | |
| SCHEMBL28096431 | 0.72 | THRB (0.38) | THRBLMNA | |
| SCHEMBL14235299 | 0.71 | LMNA (0.39) | LMNA | |
| SCHEMBL3034953 | 0.71 | CTSK (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365209-B2 | Nitrogen heterocycle biaryls for osteoporosis and other diseases | PHARMACOPEIA, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | MSR1, EDNRA, GPR174 | THRB 733/4885LMNA 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.